Losartan and amlodipine on myocardial structure and function: A prospective, randomized, clinical trial

Diabetic Medicine

Volumn 29, Issue 1, 2012, Pages 24-31

  Fogari, R ^a   Mugellini, A ^a   Destro, M ^a   Corradi, L ^a   Lazzari, P ^a   Zoppi, A ^a   Preti, P ^a   Derosa, G ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Amlodipine; Hypertension; Losartan; Myocardial structure; Type2 diabetes mellitus

Indexed keywords

AMLODIPINE; LOSARTAN; PLACEBO;

ADULT; ANKLE EDEMA; ARTICLE; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIASTOLE; ECHOCARDIOGRAPHY; FEMALE; FIBROSIS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; MIDDLE AGED; MYOCARDIUM; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 83155192744     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03383.x     Document Type: Article

References (30)

1. Levy D, Garrison RJ, Savage DD, Kannel WB. Prognostic complications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
2. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection and prognosis. Circulation 2000; 102: 470-479.
3. Nielsen FS, Ali S, Rossing P, Bang LE, Svendsen TL, Gall MA et al. Left ventricular hypertrophy in non-insulin-dependent diabetic patients with and without diabetic nephropathy. Diabet Med 1997; 14: 538-546.
4. Palmieri V, Bella JN, Arnett DK, Liu JE, Oberman A, Schuck MY et al. Effects of type2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) Study. Circulation 2001; 103: 102-107.
5. Levy D, Salomon M, D'Agostino RN, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90: 1786-1793.
6. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010.
7. Fleischmann EH, Schmieder RE. Are all antihypertensive drug classes equal in reducing left ventricular hypertrophy? Curr Cardiol Rep 2002; 4: 474-478.
8. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41-46.
9. Varo N, Iraburu MJ, Varela M, Lopez B, Etaya LC, Diez J. Losartan inhibits post-transcriptional synthesis of collagen typeI and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens 1999; 17: 107-114.
10. Tokuda K, Kai H, Kuwahara F, Yasukawa H, Tahara N, Kudo H et al. Pressure-independent effects of angiotensinII on hypertensive myocardial fibrosis. Hypertension 2004; 43: 499-503.
11. Lopez B, Querejeta R, Varo N, González A, Larman M, Martínez Ubago JL et al. Usefulness of serum carboxy-terminal pro-peptide of procollagen type1 in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001; 104: 286-291.
12. Masuyama T, St Goar FG, Tye TL, Oppenheim G, Schnittger I, Popp LR. Ultrasonic tissue characterization of human hypertrophied hearts in vivo with cardiac cycle-dependent variation in integrated backscatter. Circulation 1989; 80: 925-934.
13. Lythall DA, Bishop J, Greenbaum RA, Ilsley CJ, Mitchell AG, Gibson DG et al. Relationship between myocardial collagen and echo amplitude in non fibrotic hearts. Eur Heart J 1993; 14: 344.
14. Di Bello V, Pedrinelli R, Giorgi D, Bertini A, Talarico L, Caputo MT. Ultrasonic videodensitometric analysis of two different models of left ventricular hypertrophy: athlete's heart and hypertension. Hypertension 1997; 29: 937-944.
15. Hall CS, Scott MJ, Lanza GM, Miller JG, Wickline SA. The extracellular matrix is an important source of ultrasound backscatter from myocardium. J Acoust Soc Am 2000; 107: 612-619.
16. Hoyt RM, Skorton DJ, Collins SM, Melton HE Jr. Ultrasonic backscatter and collagen in normal ventricular myocardium. Circulation 1984; 69: 775-782.
17. Naito J, Masuyama T, Mano T, Kondo H, Yamamoto K, Nagano R et al. Ultrasonic myocardial tissue characterization in patients with dilated cardiomiopathy: value in non-invasive assessment of myocardial fibrosis. Am Heart J 1996; 131: 115-121.
18. Naito J, Koretsune Y, Sakamoto N, Shutta R, Yoshida J, Yasuoka Y et al. Transmural heterogeneity of myocardial integrated backscatter in diabetic patients without overt cardiac disease. Diabetes Res Clin Pract 2001; 52: 11-20.
19. Maceira AM, Barba J, Varo N, Beloqui O, Diez J. Ultrasonic backscatter and serum marker of cardiac fibrosis in hypertensives. Hypertension 2002; 39: 923-928.
20. Maceira AM, Barba J, Beloqui O, Diez J. Ultrasonic backscatter and diastolic function in hypertensive patients. Hypertension 2002; 40: 239-243.
21. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2010; 33: S1-S61.
22. Martina B, Dieterle T, Weinbacher M, Battegay E. Effects of losartan titrated to losartan/hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild to moderate hypertension. A double-blind randomized controlled study. Cardiology 1999; 92: 110-114.
23. Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004; 43: 2116-2123.
24. Mizuta Y, Kai H, Mizoguchi M, Osada K, Tahara N, Nakaura H et al. Long-term treatment with valsartan improved cyclic variation of the myocardial integrated backscatter signal and diastolic dysfunction in hypertensive patients: the echocardiographic assessment. Hypertens Res 2008; 31: 1835-1842.
25. Kashina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signaling and function. Blood Press 2003; 12: 70-88.
26. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000; 15: 264-272.
27. Osey SY, Price DA, Laffel LMB, Lansang MC, Hollenberg NK. Effect of angiotensinII antagonist eprosartan on hyperglycemia-induced activation of internal renin-angiotensin system in healthy humans. Hypertension 2000; 36: 122-126.
28. Sechi LA, Griffin CA, Schambelan M. The cardiac renin-angiotensin system in STZ-induced diabetes. Diabetes 1994; 43: 1180-1184.
29. Diez J, Laviades C, Monreal I, Gil MJ, Panizo A, Pardo J. Toward the biochemical assessment of myocardial fibrosis in hypertensive patients. Am J Cardiol 1995; 76: 14D-17D.
30. Guo CY, Shen LH, Li HW, Teng YX, Zhao SM. Relation of haemoglobin A1c to myocardial acoustic densitometry and left ventricular diastolic function in patients with type2 diabetes mellitus and without evident heart disease. Diabetes Res Clin Pract 2009; 83: 365-370.